Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters

Inhibition of Hepatitis B Virus by AAV8-Derived CRISPR/SaCas9 Expressed From Liver-Specific Promoters

Curative therapies for chronic hepatitis B virus (HBV) infection remain a distant goal, and the persistence of stable covalently closed circular DNA (cccDNA) during HBV replication is a key barrier that is hard to break through using the drugs currently approved for HBV treatment. Due to the accurac...

Full description

Bibliographic Details
Main Authors: Kun Yan, Jiangpeng Feng, Xing Liu, Hongyun Wang, Qiaohong Li, Jiali Li, Tianmo Xu, Muhammad Sajid, Hafiz Ullah, Li Zhou, Limin Zhou, Yu Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Microbiology
Subjects:
hepatitis B virus
CRISPR/SaCas9
liver-specific promoter
adeno-associated virus
gene therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fmicb.2021.665184/full

Internet

https://www.frontiersin.org/articles/10.3389/fmicb.2021.665184/full

Similar Items